Compare Stocks: LEGN, BBIO, HALO, and BMRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$66.58 0.0%	$78.98	$48.78 ▼ $93.42	$13.02B	0.97	2.07 million shs	3.16 million shs
BMRN BioMarin Pharmaceutical	$64.06 +0.2%	$63.93	$49.26 ▼ $70.98	$12.38B	0.24	1.84 million shs	1.88 million shs
HALO Halozyme Therapeutics	$111.45 -0.9%	$97.38	$61.22 ▼ $113.47	$12.76B	0.88	1.84 million shs	2.86 million shs
LEGN Legend Biotech	$18.53 +5.2%	$20.62	$16.24 ▼ $37.50	$3.41B	0.4	1.90 million shs	2.83 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.05%	-8.01%	-18.31%	-2.99%	+27.13%
BMRN BioMarin Pharmaceutical	+0.19%	-3.54%	-3.96%	+13.38%	+17.84%
HALO Halozyme Therapeutics	-0.89%	+3.25%	+3.03%	+60.08%	+43.23%
LEGN Legend Biotech	+5.22%	0.00%	-15.08%	-36.76%	-45.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$66.58 0.0%	$78.98	$48.78 ▼ $93.42	$13.02B	0.97	2.07 million shs	3.16 million shs
BMRN BioMarin Pharmaceutical	$64.06 +0.2%	$63.93	$49.26 ▼ $70.98	$12.38B	0.24	1.84 million shs	1.88 million shs
HALO Halozyme Therapeutics	$111.45 -0.9%	$97.38	$61.22 ▼ $113.47	$12.76B	0.88	1.84 million shs	2.86 million shs
LEGN Legend Biotech	$18.53 +5.2%	$20.62	$16.24 ▼ $37.50	$3.41B	0.4	1.90 million shs	2.83 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.05%	-8.01%	-18.31%	-2.99%	+27.13%
BMRN BioMarin Pharmaceutical	+0.19%	-3.54%	-3.96%	+13.38%	+17.84%
HALO Halozyme Therapeutics	-0.89%	+3.25%	+3.03%	+60.08%	+43.23%
LEGN Legend Biotech	+5.22%	0.00%	-15.08%	-36.76%	-45.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.83	Moderate Buy	$102.61	54.12% Upside
BMRN BioMarin Pharmaceutical	2.70	Moderate Buy	$89.17	39.20% Upside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-18.17% Downside
LEGN Legend Biotech	2.47	Hold	$53.14	186.79% Upside

Current Analyst Ratings Breakdown

Latest LEGN, BBIO, HALO, and BMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
9/16/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/11/2026	LEGN Legend Biotech	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$78.00 ➝ $74.00
9/10/2026	BBIO BridgeBio Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
9/10/2026	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/10/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$60.00
9/4/2026	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$65.00
9/4/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
9/3/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/2/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$502.08M	25.92	N/A	N/A	($10.77) per share	-6.18
BMRN BioMarin Pharmaceutical	$3.22B	3.85	$2.86 per share	22.41	$31.68 per share	2.02
HALO Halozyme Therapeutics	$1.66B	7.60	$4.73 per share	23.57	$0.42 per share	265.36
LEGN Legend Biotech	$1.03B	3.49	N/A	N/A	$5.43 per share	3.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$724.93M	-$3.57	N/A	N/A	N/A	-97.03%	N/A	-61.19%	10/28/2026 (Estimated)
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	173.14	11.75	0.46	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	33.27	11.95	0.43	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	15.84	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)

Latest LEGN, BBIO, HALO, and BMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	1.23	1.17
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
HALO Halozyme Therapeutics	13.50	2.71	2.31
LEGN Legend Biotech	N/A	3.04	2.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BMRN BioMarin Pharmaceutical	98.71%
HALO Halozyme Therapeutics	97.79%
LEGN Legend Biotech	70.89%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	14.23%
BMRN BioMarin Pharmaceutical	0.68%
HALO Halozyme Therapeutics	2.50%
LEGN Legend Biotech	0.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	839	195.49 million	167.67 million	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable

LEGN, BBIO, HALO, and BMRN Headlines

Recent News About These Companies

Legend Biotech stock gains after strong quarterly figures

September 22 at 3:10 AM | ad-hoc-news.deA

Legend Biotech stock steadies as short interest stays elevated

September 21 at 12:08 PM | ad-hoc-news.deA

Legend names Ingrid Zhang as CEO

September 17, 2026 | thepharmaletter.comT

LEGN’s new CEO from Novartis paves way for buyout speculation

September 15, 2026 | msn.com

Legend Biotech Appoints Ingrid Zhang as CEO

September 15, 2026 | finance.yahoo.com

Legend Biotech taps Novartis veteran Zhang as CEO

September 15, 2026 | reuters.com

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

September 15, 2026 | globenewswire.com

Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July

September 15, 2026 | wsj.com

Tidal Investments LLC Purchases 61,023 Shares of Legend Biotech Corporation Sponsored ADR $LEGN

September 13, 2026 | marketbeat.com

Barclays Sticks to Its Buy Rating for Legend Biotech (LEGN)

September 12, 2026 | theglobeandmail.com

RBC Capital Sticks to Its Buy Rating for Legend Biotech (LEGN)

September 12, 2026 | theglobeandmail.com

Wellington Management Group LLP Acquires New Position in Legend Biotech Corporation Sponsored ADR $LEGN

September 11, 2026 | marketbeat.com

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

September 10, 2026 | globenewswire.com

Squarepoint Ops LLC Raises Holdings in Legend Biotech Corporation Sponsored ADR $LEGN

September 9, 2026 | marketbeat.com

Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Raiffeisen Bank International AG

September 5, 2026 | marketbeat.com

Legend Biotech's (LEGN) Buy Rating Reiterated at HC Wainwright

September 4, 2026 | marketbeat.com

Legend Biotech (LEGN) Heads To Morgan Stanley Conference, Is The 57% Valuation Gap Justified?

September 2, 2026 | finance.yahoo.com

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

September 1, 2026 | globenewswire.com

Legend Biotech Corporation Sponsored ADR $LEGN is Montanova Capital LLC's 4th Largest Position

September 1, 2026 | marketbeat.com

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives Average Rating of "Hold" from Brokerages

September 1, 2026 | marketbeat.com

Legend Biotech (NASDAQ:LEGN) Trading Up 4.8% - Here's Why

August 31, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN, BBIO, HALO, and BMRN Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$66.58 -0.03 (-0.05%)

Closing price 09/21/2026 04:00 PM Eastern

Extended Trading

$67.17 +0.59 (+0.88%)

As of 08:15 AM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BioMarin Pharmaceutical NASDAQ:BMRN

$64.06 +0.12 (+0.19%)

Closing price 09/21/2026 04:00 PM Eastern

Extended Trading

$64.23 +0.17 (+0.27%)

As of 08:23 AM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Halozyme Therapeutics NASDAQ:HALO

$111.45 -1.00 (-0.89%)

Closing price 09/21/2026 04:00 PM Eastern

Extended Trading

$112.39 +0.94 (+0.84%)

As of 08:15 AM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Legend Biotech NASDAQ:LEGN

$18.53 +0.92 (+5.22%)

Closing price 09/21/2026 04:00 PM Eastern

Extended Trading

$18.60 +0.06 (+0.35%)

As of 08:19 AM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LEGN, BBIO, HALO, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LEGN, BBIO, HALO, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LEGN, BBIO, HALO, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN, BBIO, HALO, and BMRN Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

BioMarin Pharmaceutical NASDAQ:BMRN

Halozyme Therapeutics NASDAQ:HALO

Legend Biotech NASDAQ:LEGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LEGN, BBIO, HALO, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LEGN, BBIO, HALO, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LEGN, BBIO, HALO, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN, BBIO, HALO, and BMRN Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

BioMarin Pharmaceutical NASDAQ:BMRN

Halozyme Therapeutics NASDAQ:HALO

Legend Biotech NASDAQ:LEGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools